Scholarlink

Objective <p>Dysglycaemia, defined as type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), increases the cardiovascular risk and prognosis. INTERASPIRE performed in 14 countries across 6 WHO regions evaluated guideline adherence and management of patients with coronary artery disease (CAD) and dysglycaemia.</p> Methods <p>A total of 4,548 CAD patients (18–80&#xa0;years) were interviewed 6&#xa0;months–2&#xa0;years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).</p> Results <p>Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.</p> Conclusions <p>The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Safi Moayad Al-Azzawy,
  • John William McEvoy,
  • Isabelle Johansson,
  • Agnieszka Adamska,
  • Guy De Backer,
  • Iris Erlund,
  • Sandra Ganly,
  • Catriona Jennings,
  • Kornelia Kotseva,
  • Gregory Y. H. Lip,
  • Linda Mellbin,
  • Kausik K. Ray,
  • Terhi Vihervaara,
  • David Wood,
  • Ana Abreu,
  • Wael Almahmeed,
  • Ade Meidian Ambari,
  • Junbo Ge,
  • Hosam Hasan-Ali,
  • Yong Huo,
  • Piotr Jankowski,
  • Rodney M. Jimenez,
  • Yong Li,
  • Syadi Mahmood Zuhdi,
  • Abel Makubi,
  • Amam Chinyere Mbakwem,
  • Lilian Mbau,
  • Jose Luis Navarro Estrada,
  • Okechukwu Samuel Ogah,
  • Elijah Nyainda Ogola,
  • Adalberto Quintero–Baiz,
  • Mahmoud Umar Sani,
  • Maria Ines Sosa Liprandi,
  • Jack Wei Chieh Tan,
  • Miguel Alberto Urina Triana,
  • Tee Joo Yeo,
  • Dirk De Bacquer,
  • Lars Rydén

摘要

Objective

Dysglycaemia, defined as type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), increases the cardiovascular risk and prognosis. INTERASPIRE performed in 14 countries across 6 WHO regions evaluated guideline adherence and management of patients with coronary artery disease (CAD) and dysglycaemia.

Methods

A total of 4,548 CAD patients (18–80 years) were interviewed 6 months–2 years after hospital admission. All without diabetes were eligible for an oral glucose test (OGTT).

Results

Overall, 1990 (44%) had known T2DM. The OGTT revealed that 808 (40%) had previously unknown dysglycaemia (T2DM 12% and IGT 28%). Two thirds of all dysglycaemic patients were obese. A similar proportion reported low physical activity and only one third received dietary advice. Only half of dysglycemic patients were prescribed all guideline recommended cardioprotective drugs. A majority did not reach recommended blood pressure, lipids or HbA1c targets. Only 16% had attended a diabetes education program.

Conclusions

The INTERASPIRE study shows that screening for glucose perturbations in coronary patients is inadequate, achievement of lifestyle recommendations suboptimal and pharmacological management insufficient resulting in a poor risk factor control. Patients with coronary disease, especially those with glucose perturbations require professional support to achieve healthier lifestyles, and prescription of all cardioprotective medications to achieve guideline targets.